Choose a Color

HPV Vaccines: Can we prevent cervical cancer around the world through vaccination?

Sharing knowledge to influence practice and solve service delivery challenges

June 16 to July 4, 2008 

This three-week discussion explored evidence and issues related to the current global situation, existing barriers, and innovative strategies for expanding access to emergency contraception (EC).  

Discussion Statistics

Number of participants: 33
Number of participants' countries: 19
Number of contributions: 80

Contributing countries:

Argentina, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Cyprus, Great Britain, India, Kenya, Marshall Islands, Nigeria, Peru, South Africa, Switzerland, Uganda, United States, Uzbekistan, Venezuela, Zimbabwe

Purpose and Objectives


To share knowledge, to influence practice and to solve service delivery challenges pertaining to HPV vaccination                                                                    


  • To link health professionals, policy-makers, and practitioners around the world to share knowledge, experience and insights in order to determine the feasibility of delivering HPV vaccines.
  • To inform WHO policy decisions regarding cervical cancer prevention and the feasibility of introducing HPV vaccines.
  • To create technical briefing papers to provide guidance on cervical cancer prevention and the feasibility of introducing HPV vaccines.                                              
Week 1. How can we include HPV vaccination in current or planned cancer control programs?  Week 2. Where budgets are restricted, how does one make decisions about prioritizing different cervical cancer control strategies?  Week 3. How do we overcome social, cultural and political barriers to ensure HPV vaccine access and delivery?  Related activities and next steps 
  • Conduct discussions and post educational resources and advocacy materials online that were identified as priorities in the needs assessment survey
  • Partner with other organizations to distribute advocacy materials, educational resources, and information about vaccine cost-effectiveness
  • Develop tool kits and technical guidance for community-level research and the development of a comprehensive, integrated approach to cervical cancer prevention
  • Transfer of technology to Latin America.
Post-forum survey results

% who have passed content to others - 93%

% very satisfied with forum content - 91%

References and resources

Planning and implementing cervical cancer prevention and control programs: a manual for managers. Corporate author(s): ACCP; EngenderHealth; IARC; JHPIEGO; PAHO; PATH Publication date: 2004

Vaccine introduction guidelines: Adding a vaccine to a national immunization programme: decision and implementation. WHO –Immunization, Vaccines and Biologicals. Publication date: 2005

Preparing for the introduction of HPV vaccines. Policy and programme guidance for countries. WHO – Reproductive Health and Research. Publication date: 2006

Human papillomavirus and HPV vaccines. Technical information for policy-makers and health professionals. WHO – Immunization, Vaccines and Biologicals. Publication date: 2007

Reports and publications

The HPV Vaccine Global Community of Practice: A model for global discussion about cervical cancer prevention and the role of HPV vaccines

HPV Vaccine Global Community of Practice: Membership& Evaluation (This poster was presented in May 2009 at the 25th International Papillomavirus Conference in Malmo, Sweden)

Facilitating HPV Vaccination Program Implementation through a Global, Online Network (This poster was presented in September 2010 at the 50th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) in Boston, Massachusetts)

Organizing groups

Cincinnati Children’s Hospital Medical Center, World Health Organization/Reproductive Health and Research,IBP Knowledge Gateway)

Contributing experts/facilitators 

Stanford University, University of Zimbabwe, McGill University, Ludwig Institute for Cancer Research, Imperial College London, World Health Organization/Reproductive Health and Research, PATH, University of Manchester, Peruvian National Institute of Health, University of Texas

Steering committee

Cincinnati Children’s Hospital Medical Center, World Health Organization, International Agency for Research on Cancer, PATH, Union for International Cancer Control, United Nations Population Fund, University of Yaounde, US Centers for Disease Control, European Cervical Cancer Association, National Institute of Health Peru, McGill University, Ludwig Institute, Royal Women and Children’s Hospital, Chinese Academy of Medical Sciences, Imperial College London, Bill and Melinda Gates Foundation and EURO, PAHO, SEARO, AFRO, WPRO, and EMRO regional offices of WHO.

Other acknowledgements

American Society for Emergency Contraception

Catholics for Choice

CLAE (Latin American Consortium for EC)


Family Violence Prevention Fund

Gynuity Health Projects


Population Council

Princeton University

Sexual Violence Research Initiative


Ibis Reproductive Health


Dr. Jessica Kahn, Cincinnati Children’s Hospital Medical Center